Completed PHASE3 INTERVENTIONAL 3-arm NCT05907122

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

A Randomized, Double-blind Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Resected Stage III or Stage IV Melanoma Subjects in the Adjuvant Setting

Sponsor: Amgen

Conditions Melanoma

Interventions ABP 206 EU-authorized Nivolumab FDA-licensed Nivolumab

Updated 21 times since 2023 Last updated: Feb 25, 2026 Started: Jul 26, 2023 Primary completion: Mar 26, 2025 Completion: Oct 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05907122, this PHASE3 trial focuses on Melanoma and remains completed. Sponsored by Amgen, it has been updated 21 times since 2023, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

21 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE3
Dec 2025 — Feb 2026 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Nov 2025 — Dec 2025 [monthly]

Active Not Recruiting PHASE3
Sep 2025 — Nov 2025 [monthly]

Active Not Recruiting PHASE3
Dec 2024 — Sep 2025 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting

▶ Show 16 earlier versions

Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE3
Oct 2024 — Nov 2024 [monthly]

Recruiting PHASE3
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE3
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE3
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE3
May 2024 — Jun 2024 [monthly]

Recruiting PHASE3
Apr 2024 — May 2024 [monthly]

Recruiting PHASE3
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE3
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE3
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE3
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE3
Nov 2023 — Dec 2023 [monthly]

Recruiting PHASE3
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE3
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Jul 2023 — Sep 2023 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen

Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bangkok, Thailand , Banja Luka, Bosnia and Herzegovina , Barcelona, Spain , Barretos, Brazil , Belgrade, Serbia , Belém, Brazil , Billings, United States , Brasília, Brazil , Breda, Netherlands , Bucharest, Romania and 60 more locations